1921
Volume 96, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

A Jarisch–Herxheimer reaction (JHR) may be precipitated after initiation of chemotherapy in spirochetal diseases, including leptospirosis. However, a clear idea of the importance of JHR in this disease is lacking. The incidence of and risk factors for JHR were investigated retrospectively among 262 patients with confirmed leptospirosis who received amoxicillin treatment in New Caledonia and Futuna. The overall rate of JHR was 21% (12% in New Caledonia and 44% in Futuna). Two risk factors were independently associated with JHR occurrence: serogroup Australis as the infecting strain (odds ratio [OR] = 2.60, confidence interval [CI] = 1.40–5.62) and delays < 3 days between the onset of symptoms and the initiation of antibiotherapy (OR = 2.14, CI = 1.11–4.38). Clinicians should be aware of JHR as a potential complication of leptospirosis. Strain-related factors associated with JHR occurrence and its impact on outcome remains to be explored.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0457
2017-04-05
2018-10-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/96/4/791.html?itemId=/content/journals/10.4269/ajtmh.16-0457&mimeType=html&fmt=ahah

References

  1. Costa F, Hagan J, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, Stein C, Abela-Ridder B, Ko AI, , 2015. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis 9: e0003898.[Crossref]
  2. Berlioz-Arthaud A, Kiedrzynski T, Singh N, , 2007. Multicentre survey of incidence and public health impact of leptospirosis in the western Pacific. Trans R Soc Trop Med Hyg 101: 714721.[Crossref]
  3. Massenet D, Yvon JF, Couteaux C, Goarant C, , 2015. An unprecedented high incidence of leptospirosis in Futuna, South Pacific, 2004–2014, evidenced by retrospective analysis of surveillance data. PLoS One 10: e0142063.[Crossref]
  4. World Health Organization (WHO), International Leptospirosis Society (ILS) WHO-ILS, 2003. Human Leptospirosis: Guidance for Diagnosis, Surveillance and Control. , ed. Geneva, Switzerland: World Health Organization. Available at: http://apps.who.int/iris/bitstream/10665/42667/1/WHO_CDS_CSR_EPH_2002.23.pdf. Accessed March 11, 2016.
  5. Jarisch A, , 1895. Therapeutische versuche bei Syphilis. Wien Med Wochenschr 45: 721724.
  6. Herxheimer K, Krause D, , 1902. Ueber eine bei Syphilistischen vorkommende Quecksilberreaktion. Dtsch Med Wochenschr 28: 895897.[Crossref]
  7. Bryceson AD, , 1976. Clinical pathology of the Jarisch-Herxheimer reaction. J Infect Dis 133: 696704.[Crossref]
  8. Pound MW, May DB, , 2005. Proposed mechanisms and preventative options of Jarisch-Herxheimer reactions. J Clin Pharm Ther 30: 291295.[Crossref]
  9. Yang C, Lee NY, Lee HC, , 2010. Jarisch-Herxheimer reaction after penicillin therapy among patients with syphilis in the era of the HIV infection epidemic: incidence and risk factors. Clin Infect Dis 51: 976979.[Crossref]
  10. Maloy AL, Black RD, Segurola RJ, Jr, 1998. Lyme disease complicated by the Jarisch-Herxheimer reaction. J Emerg Med 16: 437438.[Crossref]
  11. Dworkin MS, Anderson DE, Jr Schwan TG, , 1998. Tick-borne relapsing fever in the northwestern United States and southwestern Canada. Clin Infect Dis 26: 122123.[Crossref]
  12. Fekade D, Knox K, Hussein K, , 1996. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med 335: 311315.[Crossref]
  13. Guerrier G, D'Ortenzio E, , 2013. The Jarisch-Herxheimer reaction in leptospirosis: a systematic review. PLoS One 8: e59266.[Crossref]
  14. Janier M, Hegyi V, Dupin NM, Unemo M, Tiplica GS, Potočnik M, French P, Patel R, , 2014. European Guideline on the Management of Syphilis. Available at: http://www.iusti.org/regions/europe/pdf/2014/2014SyphilisguidelineEuropean.pdf. Accessed March 13, 2016.
  15. Workowski KA, Bolan GA, Centers for Disease Control and Prevention; , 2015. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 64: 1137. Available at: https://www.cdc.gov/std/tg2015/tg-2015-print.pdf. Accessed March 3, 2016 [Crossref]
  16. Brett-Major DM, Coldren R, , 2012. Antibiotics for leptospirosis. Cochrane Database Syst Rev 15: CD008264.
  17. Dupont H, Dupont-Perdrizet D, Perie JL, , 1997. Leptospirosis: prognostic factors associated with mortality. Clin Infect Dis 25: 720724.[Crossref]
  18. Spichler AS, Vilaça PJ, Athanazio DA, , 2008. Predictors of lethality in severe leptospirosis in urban Brazil. Am J Trop Med Hyg 79: 911914.
  19. Rajapakse S, Weeratunga P, Niloofa R, Fernando N, Lakshitha de Silva N, Rodrigo C, Maduranga S, Nandasiri N, Premawansa S, Karunanayake L, Janaka de Silva H, Handunnetti S, , 2016. A diagnostic scoring model for leptospirosis in resource limited settings. PLoS Negl Trop Dis 10: e0004513.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0457
Loading
/content/journals/10.4269/ajtmh.16-0457
Loading

Data & Media loading...

  • Received : 08 Jun 2016
  • Accepted : 12 Dec 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error